PsychedelicNewsBreaks – MindSite News Launches Conversation Series on Psychedelic Resurgence for Mental Health and Wellness

MindSite News — the only news site dedicated exclusively to reporting on mental health in America—today announced that it is launching a live public conversation series. Taking place throughout the month of October, the series is designed to engage the public in conversations about psychedelics and mental health. The campaign also aims to raise funds to support MindSite’s nonprofit journalism and ongoing coverage of this important topic. In the live virtual series hosted by MindSite News, founding editor Rob Waters will be in conversation with key thought leaders to examine the psychedelic resurgence and its potential for bringing healing and wellness, as well as the potential pitfalls of these efforts. With society at a pivotal moment and policy and cultural change occurring at state and federal levels, MindSite News is poised to play a role as an independent news source dedicated to rigorous, inclusive reporting on the space.

To view the full press release, visit https://ibn.fm/SsUGG

About MindSite News

MindSite News is the only news outlet dedicated exclusively to covering mental health in America, and is excited to join these other psychedelic-focused media outlets to discuss the nonprofit media organization’s own philosophies about reporting on both the flaws and successful innovations in this space. Register for this conversation here.

Today about 30% of adult Americans are grappling with mental illness and substance use disorders — and psychedelic therapies show promise. Once relegated to the countercultural fringe, there is now an explosion of serious scientific research. The potential for psychedelic drugs to be used as legitimate therapies is rapidly gaining recognition and legal status.

Sign up for MindSite News daily updates on all things mental health, and consider supporting nonprofit journalism that covers mental health – with depth and context.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated…

6 hours ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update…

6 hours ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21

NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present…

1 day ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs

NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs,…

2 weeks ago

PsychedelicNewsBreaks – NextPlat Corp. (NASDAQ: NXPL, NXPLW) Reports Q3 2025 Results Highlighted by Cost Reductions and Improving Healthcare Trends

NextPlat (NASDAQ: NXPL, NXPLW) reported third-quarter 2025 results showing consolidated revenue of about $13.8 million…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter…

3 weeks ago